Researchers found that blocking IL1RAP could disrupt a powerful inflammatory network that helps pancreatic cancer survive treatment. In preclinical experiments, the approach reduced tumor-protecting cells and fibrosis while boosting the activity of cancer-fighting T cells. That could make chemotherapy and immunotherapy more effective.